Eli Lilly provided a strategic anchor investment in Aktis Oncology’s upsized IPO, which raised approximately $318 million through the sale of 17.65 million shares priced at $18 each. Lilly’s support underscored strong institutional demand and validated Aktis’s pipeline of alpha-emitting radiopharmaceuticals targeting solid tumors. The offering, managed by J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen, positions Aktis to advance its lead candidates AKY-1189 and AKY-2519 through late-stage clinical trials and scale manufacturing, while Lilly retains a significant equity stake and collaboration rights valued up to $1.2 billion for co-developed assets.

Eli Lilly has entered a multi-year agreement with Chai Discovery to deploy the latter’s frontier artificial intelligence platform for novel biologic design. Under the deal, Lilly will fund development of a custom AI model trained on proprietary data, aiming to shorten early-stage discovery timelines from months to weeks. This partnership follows Lilly’s evaluation of Chai-2 designs, which delivered double-digit experimental hit rates in zero-shot antibody screens. The collaboration builds on Chai’s recent $1.3 billion valuation in a Series B round co-led by Oak HC/FT and General Catalyst, and signals Lilly’s commitment to in-house AI capabilities for target validation and candidate optimization.

Late-stage results from the TOGETHER-PsA study demonstrate that combining Lilly’s psoriatic arthritis agent with its weight-loss therapy significantly enhances clinical outcomes. The dual regimen achieved a 31.7% improvement rate in joint and skin symptom criteria versus 0.8% for monotherapy, and recorded a 64% relative increase in ACR50 response. Patients receiving the combination also experienced substantial weight reductions consistent with Zepbound’s safety profile. Adverse events were predominantly mild to moderate, aligning with known tolerability patterns and reinforcing Lilly’s strategy of leveraging metabolic benefits to augment immunology treatments.